CGH
ACOR

Crossmark Global Holdings’s Acorda Therapeutics ACOR Stock Holding History

Crossmark Global Holdings’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-67
Closed -$229K – 1609
2018
Q2 		$229K Buy
+67
New +$205K 0.01% 1475
2018
Q1 		– Sell
-82
Closed -$210K – 1639
2017
Q4 		$210K Hold
82
– – 0.01% 1560
2017
Q3 		$233K Buy
+82
New +$216K 0.01% 1481
2016
Q3 		$233K Buy
+82
New +$245K 0.01% 1481

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Crossmark Global Holdings's ACOR Position: Q3 2018 in Review

Crossmark Global Holdings sold out of Acorda Therapeutics (ACOR) in Q3 2018, closing a stake of 67 shares — an estimated $229K sold.

Crossmark Global Holdings first reported a position in ACOR in Q3 2016 and held it in 4 quarters. The position peaked at $233K in Q3 2017. 174 funds tracked by Wall St. Rank hold ACOR as of Q3 2018.

  • Crossmark Global Holdings reported no remaining Acorda Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Crossmark Global Holdings sold 67 Acorda Therapeutics shares in Q3 2018, an estimated $229K.
  • Crossmark Global Holdings first reported a position in Acorda Therapeutics in Q3 2016 and held it in 4 quarters.
  • Crossmark Global Holdings's Acorda Therapeutics position peaked at $233K in Q3 2017.
  • 174 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2018.

Based on Crossmark Global Holdings's 13F filing for Q3 2018, filed 6 Nov 2018.